VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

E. coli FimH with CFA and then IFA
Vaccine Information
  • Type: Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: E. coli FimH (Langermann et al., 1997)
  • FimH from E. coli str. K-12 substr. MG1655 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Baboon Response

  • Vaccination Protocol: C3H mice were immunized with the various FimH vaccines and challenged with the NU14 clinical isolate 9 weeks after the primary immunization.
  • Challenge Protocol: Intraurethral inoculation of C3H mice with 5 × 107 type 1–piliated E. coli (strain NU14) resulted in a highly reproducible colonization of the mouse bladder (Langermann et al., 1997). Piliated bacteria persisted in the bladder for at least 7 days [104 colony-forming units (CFU)/bladder] and produced ascending infection into the kidney.
  • Efficacy: Vaccinated animals exhibited a 100- to 1000-fold reduction in the number of organisms recovered from the bladders as compared with adjuvant- or FimC-immunized controls (Langermann et al., 1997).
References
Langermann et al., 1997: Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (New York, N.Y.). 1997; 276(5312); 607-611. [PubMed: 9110982].